Anti-CD19 CAR-T cell therapy is approved for patients up to 25 years of age and for adult affect by ALL based on the ELIANA (tisagenlecleucel-tisa-cel) (18) and ZUMA-3 trial (brexucabtagene autoleucel – brex-cel) (19). Here, CD19 is linked to acute lymphoblastic leukemia.